Coherus Historical Income Statement

CHRS Stock

USD 1.26 0.02 1.56%

Historical analysis of Coherus BioSciences income statement accounts such as Interest Expense of 42.6 M, Selling General Administrative of 100.1 M or Total Revenue of 172.9 M can show how well Coherus BioSciences performed in making a profits. Evaluating Coherus BioSciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Coherus BioSciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Coherus BioSciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Coherus BioSciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coherus BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.

About Coherus Income Statement Analysis

Coherus BioSciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Coherus BioSciences shareholders. The income statement also shows Coherus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Coherus BioSciences Income Statement Chart

At this time, Coherus BioSciences' Interest Expense is comparatively stable compared to the past year. Gross Profit is likely to gain to about 141.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 100.1 M in 2024.

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses Non Operating Income Net Other

Total Revenue

Total revenue comprises all receipts Coherus BioSciences generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Coherus BioSciences minus its cost of goods sold. It is profit before Coherus BioSciences operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Coherus BioSciences. It is also known as Coherus BioSciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Coherus BioSciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Coherus BioSciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coherus BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.At this time, Coherus BioSciences' Interest Expense is comparatively stable compared to the past year. Gross Profit is likely to gain to about 141.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 100.1 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	23.0M	32.5M	40.5M	42.6M
Depreciation And Amortization	5.7M	3.7M	3.8M	2.0M

Interest Expense Depreciation And Amortization

Coherus BioSciences income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Net Interest Income	Reconciled Depreciation	Tax Provision	Selling And Marketing Expenses
Depreciation And Amortization		0.64	0.74	0.72	0.59	0.8	-0.2	-0.2	0.58	-0.18	-0.09	0.74	-0.26	-0.71	-0.29	0.37	-0.2	0.37	0.64	-0.67	0.09	-0.54	0.63
Interest Expense	0.64		0.84	0.63	0.46	0.74	-0.29	-0.27	0.35	-0.26	-0.03	0.64	-0.37	-0.86	-0.38	0.3	-0.3	0.52	0.91	-0.98	0.51	-0.88	0.8
Selling General Administrative	0.74	0.84		0.76	0.61	0.9	-0.27	-0.26	0.52	-0.25	0.01	0.83	-0.34	-0.75	-0.37	0.48	-0.24	0.75	0.92	-0.82	0.24	-0.67	0.75
Total Revenue	0.72	0.63	0.76		0.96	0.7	0.28	0.28	0.46	0.29	-0.14	0.68	0.21	-0.64	0.17	0.23	0.31	0.56	0.79	-0.59	-0.18	-0.3	0.35
Gross Profit	0.59	0.46	0.61	0.96		0.57	0.41	0.41	0.45	0.42	-0.18	0.6	0.35	-0.49	0.31	0.18	0.45	0.53	0.68	-0.4	-0.37	-0.09	0.11
Other Operating Expenses	0.8	0.74	0.9	0.7	0.57		-0.48	-0.48	0.83	-0.46	0.26	0.98	-0.54	-0.7	-0.56	0.45	-0.44	0.72	0.82	-0.71	0.3	-0.66	0.73
Operating Income	-0.2	-0.29	-0.27	0.28	0.41	-0.48		1.0	-0.54	1.0	-0.51	-0.48	0.99	0.19	0.99	-0.31	0.99	-0.29	-0.17	0.29	-0.68	0.58	-0.57
Ebit	-0.2	-0.27	-0.26	0.28	0.41	-0.48	1.0		-0.55	1.0	-0.52	-0.48	0.99	0.21	0.99	-0.28	0.99	-0.27	-0.15	0.27	-0.67	0.57	-0.56
Research Development	0.58	0.35	0.52	0.46	0.45	0.83	-0.54	-0.55		-0.54	0.45	0.91	-0.57	-0.37	-0.58	0.33	-0.48	0.61	0.49	-0.3	0.13	-0.34	0.36
Ebitda	-0.18	-0.26	-0.25	0.29	0.42	-0.46	1.0	1.0	-0.54		-0.52	-0.47	0.99	0.19	0.99	-0.28	0.99	-0.27	-0.14	0.26	-0.67	0.56	-0.55
Cost Of Revenue	-0.09	-0.03	0.01	-0.14	-0.18	0.26	-0.51	-0.52	0.45	-0.52		0.29	-0.5	0.04	-0.47	-0.26	-0.45	0.31	-0.03	0.05	0.24	-0.06	0.09
Total Operating Expenses	0.74	0.64	0.83	0.68	0.6	0.98	-0.48	-0.48	0.91	-0.47	0.29		-0.53	-0.61	-0.56	0.46	-0.43	0.76	0.77	-0.59	0.2	-0.55	0.6
Income Before Tax	-0.26	-0.37	-0.34	0.21	0.35	-0.54	0.99	0.99	-0.57	0.99	-0.5	-0.53		0.29	1.0	-0.31	0.99	-0.32	-0.24	0.37	-0.7	0.64	-0.63
Total Other Income Expense Net	-0.71	-0.86	-0.75	-0.64	-0.49	-0.7	0.19	0.21	-0.37	0.19	0.04	-0.61	0.29		0.32	-0.12	0.2	-0.32	-0.74	0.87	-0.45	0.78	-0.75
Net Income	-0.29	-0.38	-0.37	0.17	0.31	-0.56	0.99	0.99	-0.58	0.99	-0.47	-0.56	1.0	0.32		-0.36	0.98	-0.33	-0.26	0.39	-0.7	0.65	-0.65
Income Tax Expense	0.37	0.3	0.48	0.23	0.18	0.45	-0.31	-0.28	0.33	-0.28	-0.26	0.46	-0.31	-0.12	-0.36		-0.34	0.27	0.37	-0.31	0.2	-0.37	0.44
Net Income From Continuing Ops	-0.2	-0.3	-0.24	0.31	0.45	-0.44	0.99	0.99	-0.48	0.99	-0.45	-0.43	0.99	0.2	0.98	-0.34		-0.2	-0.14	0.31	-0.73	0.62	-0.61
Non Operating Income Net Other	0.37	0.52	0.75	0.56	0.53	0.72	-0.29	-0.27	0.61	-0.27	0.31	0.76	-0.32	-0.32	-0.33	0.27	-0.2		0.76	-0.43	-0.09	-0.26	0.26
Interest Income	0.64	0.91	0.92	0.79	0.68	0.82	-0.17	-0.15	0.49	-0.14	-0.03	0.77	-0.24	-0.74	-0.26	0.37	-0.14	0.76		-0.86	0.22	-0.67	0.63
Net Interest Income	-0.67	-0.98	-0.82	-0.59	-0.4	-0.71	0.29	0.27	-0.3	0.26	0.05	-0.59	0.37	0.87	0.39	-0.31	0.31	-0.43	-0.86		-0.57	0.91	-0.85
Reconciled Depreciation	0.09	0.51	0.24	-0.18	-0.37	0.3	-0.68	-0.67	0.13	-0.67	0.24	0.2	-0.7	-0.45	-0.7	0.2	-0.73	-0.09	0.22	-0.57		-0.83	0.77
Tax Provision	-0.54	-0.88	-0.67	-0.3	-0.09	-0.66	0.58	0.57	-0.34	0.56	-0.06	-0.55	0.64	0.78	0.65	-0.37	0.62	-0.26	-0.67	0.91	-0.83		-0.93
Selling And Marketing Expenses	0.63	0.8	0.75	0.35	0.11	0.73	-0.57	-0.56	0.36	-0.55	0.09	0.6	-0.63	-0.75	-0.65	0.44	-0.61	0.26	0.63	-0.85	0.77	-0.93

Click cells to compare fundamentals

Coherus BioSciences Account Relationship Matchups

Coherus BioSciences income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	171.9K	5.0M	5.7M	3.7M	3.8M	2.0M
Interest Expense	17.6M	21.2M	23.0M	32.5M	40.5M	42.6M
Selling General Administrative	132.5M	135.3M	161.0M	188.0M	192.0M	100.1M
Total Revenue	356.1M	475.8M	326.6M	211.0M	257.2M	172.9M
Gross Profit	339.0M	438.2M	269.0M	141.0M	94.5M	141.2M
Other Operating Expenses	248.3M	319.5M	590.4M	467.9M	460.4M	298.4M
Operating Income	107.8M	156.3M	(263.9M)	(256.9M)	(203.2M)	(193.0M)
Ebit	110.2M	156.9M	(266.3M)	(259.3M)	(197.7M)	(187.8M)
Research Development	94.2M	142.8M	363.1M	199.4M	109.4M	164.4M
Ebitda	110.4M	161.8M	(260.7M)	(255.6M)	(193.9M)	(184.2M)
Cost Of Revenue	17.1M	37.7M	57.6M	70.1M	162.8M	83.5M
Total Operating Expenses	231.2M	281.8M	532.8M	397.8M	301.5M	267.1M
Income Before Tax	92.8M	135.7M	(287.1M)	(291.8M)	(238.3M)	(226.4M)
Total Other Income Expense Net	(15.0M)	(20.6M)	(23.2M)	(34.9M)	(35.1M)	(33.3M)
Net Income	89.8M	132.2M	(306.3M)	(326.6M)	(237.9M)	(226.0M)
Income Tax Expense	2.9M	3.5M	19.2M	34.9M	(380K)	(361K)
Net Income From Continuing Ops	89.8M	132.2M	(287.1M)	(291.8M)	(237.9M)	(226.0M)
Non Operating Income Net Other	2.6M	554K	(283K)	(2.4M)	(2.8M)	(2.9M)
Net Income Applicable To Common Shares	89.8M	132.2M	(287.1M)	(291.8M)	(262.6M)	(249.4M)
Net Interest Income	(17.6M)	(21.2M)	(23.0M)	(32.5M)	(40.5M)	(38.5M)
Reconciled Depreciation	3.3M	2.9M	3.5M	3.7M	3.8M	3.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Coherus Stock Analysis

When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Coherus Historical Income Statement

About Coherus Income Statement Analysis

Coherus BioSciences Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Coherus BioSciences income statement Correlations

Coherus BioSciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Coherus BioSciences income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Coherus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Income Before Tax	+ 0.99	Operating Income
Net Income	+ 0.99	Operating Income

Net Interest Income	- 0.98	Interest Expense
Selling And Marketing Expenses	- 0.93	Tax Provision
Tax Provision	- 0.88	Interest Expense
Net Interest Income	- 0.86	Interest Income
Total Other Income Expense Net	- 0.86	Interest Expense
Selling And Marketing Expenses	- 0.85	Net Interest Income